Next, we investigated in vivo cDC1 reprogramming as monotherapy or in combination with either anti-PD-1 or anti-CTLA-4 using B16, B2905 and the additional melanoma model YUMM1.7, which is resistant to ICB and also depends on cDC1 availability (11, 24, 26). This evidence concerns the gene CTLA4 and melanoma.